Loading...
Research Publications2025-11-12T18:18:11+11:00

Our research is published in leading national and international journals to share the results of our studies with peers around the world.

2025

Lombard J., Davis A., Mandaliya H., Meniiawy T., Quah G., Cellimarchiett G., Briscoe K., Campbell R., Beale P., Kelly B., Bressel M., Beatty L., Ritchie G., Pugliese L., Alsop K., Ford C., Marsh D., Jeon M., Stojanova J., Stannard G., Bowden N. REPURPOSE: Phase II study assessing the efficacy of efavirenz, an approved HIV drug repurposed as an anti-cancer agent, in patients with platinum resistant ovarian cancer. International Journal of Gynecological Cancer, 35(11 Suppl 1), Nov 2025, 102173. https://www.international-journal-of-gynecological-cancer.com/article/S1048-891X(25)01293-9/abstract

Lee C.K., Kartikasari A.E.R., Bound N.T., Francis K.E., Shield-Artin K., Bedo J., Nesic K., Diamante K., O’Connell R.L., Madondo M., Cox M., Davies C., Deceneux C., Goodchild G., Jarratt A., Cassar E., Amer H., Kariyawasam I.U., Lee Y.C., Lombard J., Baron-Hay S., Antill Y., Shannon C., Selva-Nayagam S., Plebanski M. (2025). Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial. Nature Communications, 16, Article 9756. https://doi.org/10.1038/s41467-025-64130-6

Cathalijne C B Post, Stephanie M de Boer, Melanie E Powell, Linda Mileshkin, Dionyssios Katsaros, Paul Bessette, Alexandra Leary, Petronella B Ottevanger, Mary McCormack, Pearly Khaw, Romerai D’Amico, Anthony Fyles, Cyrus Chargari, Henry C Kitchener, Viet Do, Andrea Lissoni, Prof Diane Provencher, Catherine Genestie, Hans W Nijman, Karen Whitmarsh, Ina M Jürgenliemk-Schulz, Amanda Feeney, Ludy C H W Lutgens, Jeanette Bouma, Alicia Leon-Castillo, Remi A Nout, Hein Putter, Tjalling Bosse, Carien L Creutzberg. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial.
The Lancet Oncology. 2025; Published September 5, 2025. DOI: 10.1016/S1470‑2045(25)00379‑1

Natalie Y L Ngoi, Chel Hun Choi, Junxian Zhu, Diana Lim, Tuan Zea Tan, Haoyang Sun, Valerie Heong, Samuel G W Ow, Wen Yee Chay, Hee Seung Kim, Yi Wan Lim, Siew Eng Lim, Geraldine Goss, Jeffrey C Goh, Jae-Weon Kim, Michael Friedlander, Bee Choo Tai, Kidong Kim, David S P Tan. Durvalumab versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): a multicenter, randomized, phase 2 trial
Clinical Cancer Research, 2025 Jul 24
DOI: 10.1158/1078-0432.CCR-25-0201

Rachel Grisham, Bradley J. Monk, Els Van Nieuwenhuysen, Kathleen Nadine Moore, Michel Fabbro, David M. O’Malley, Ana Oaknin, Premal Thaker, Amit M. Oza, Nicoletta Colombo, David Gershenson, Carol A. Aghajanian, Chel Hun Choi, Yeh Chen Lee, Mansoor Raza Mirza, Robert L. Coleman, Lauren Cobb, Philipp Harter, Stephanie Lustgarten, Hagop Youssoufian, Susana Banerjee. GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer
International Journal of Gynecological Cancer. (Apr-25;Articles in Press).
doi: 10.1136/ijgc-2024-005919.

François Cherifi, Isabelle Ray-Coquard, Maria Jesus Rubio, Xavier Paoletti, Domenica Lorusso, Chel Hun Choi, Kosei Hasegawa, David Shao Peng Tan, Emma Hudson, Alison Davis, Germana Tognon, Stéphanie Lheureux, Mehmet Ali Vardar Key, Jean Emmanuel Kurtz, Jerome Alexandre & Florence Joly (05 May 2025): DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients,
Future Oncology, (05 May 2025)
DOI: 10.1080/14796694.2025.2496133 Read here

Jolijn Boer, Alison Brand, Rosalind Glasspool, Chee Khoon Lee, Veronika Seebacher-Shariat, Paul A. Cohen, Toon Van Gorp, Adriana Chavez Blanco, Hanna Hranovska, Jose Alejandro Pérez-Fidalgo, Bhavana Pothuri, Noriko Fujiwara, Hiroshi Nishio, Se Ik Kim, Asima Mukhopadhyay, Sabrina Chiara Cecere, Elise Kohn, Kristina Lindemann, Xiaojun Chen, Jalid Sehouli. Minimal Required Data Set For Gynecological Cancer Trials: The GCIG Statement From The Barcelona Meeting
International Journal of Gynecological Cancer. (Feb-25; Volume 35, Issue 2, Supplement 1).
doi: 10.1016/j.ijgc.2024.101565.

Jalid Sehouli, Amit Oza, Jennifer O’Donnell, Katherine Bennett, Josée-Lyne Ethier, Philipp Harter, Ting-Chang Chang, Sharon O’Toole, Christianne Lok, Ainhoa Madariaga, Jose Alejandro Rauh-Hain, David Sp Tan, Judith Michels, Ora Rosengarten, Elisa Piovano, Uma Mukherjee, Sara Nasser, Jennifer Croke, Franziska Geissler, Michael Bookman. Increasing Diversity In Gynaecological Cancer Trials: The GCIG Statement From The Barcelona Meeting
International Journal of Gynecological Cancer. (Feb-25; Volume 35, Issue 2).
doi: 10.1016/j.ijgc.2024.101566.

Desislava Dimitrova, Jolijn Boer, Murat Karaman, Michael Bookman, Alison Brand, Jennifer O’Donnell, Amit Oza, Bhavana Pothuri, Katherine Bennett, Jalid Sehouli. Perspectives on inclusion, diversity, equity, and access in clinical trials: findings from a 6-continent survey
International Journal of Gynecological Cancer. (Feb 25; Volume 35, Issue 2).
doi: 10.1016/j.ijgc.2024.101625.

Pauline M. Maki, Leah H. Rubin, Efrosinia O. Krejany, Alison Brand, Martha Hickey. What happens after menopause? (WHAM): A prospective controlled study of cognition 24 months after premenopausal risk-reducing salpingo-oophorectomy
Gynecologic Oncology. (Feb 25;Volume 193).
doi: 10.1016/j.ygyno.2025.01.008.

Desislava Dimitrova, Jolijn Boer, Murat Karaman, Michael Bookman, Alison Brand, Jennifer O’Donnell, Amit Oza, Bhavana Pothuri, Katherine Bennett, Jalid Sehouli. Mapping The Global Landscape Of Inclusion, Diversity, Equity, And Access In Clinical Trials: Perspectives From Gynaecologic Research Groups
International Journal of Gynecological Cancer. (Feb 25;Volume 35, Issue 2, Supplement 1).
doi: 10.1016/j.ijgc.2024.100427.

Lucy Haggstrom, Yeh Chen Lee, Clare Scott, Philipp Harter, Linn Woelber, Jonathan Ledermann, Charlie Gourley, Iain A McNeish, Frédéric Amant, Isabelle Ray-Coquard, Alexandra Leary, Amit M Oza, Anna Tinker, Antonio González Martin, Sabrina Chiara Cecere, Sandro Pignata, Nicoletta Colombo, Hiroyuki Yoshida, Christian Marth, Ora Rosengarten, Kathleen Nadine Moore, Eva María Gómez-García, David Tan, Michael L Friedlander. How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes
International Journal of Gynecological Cancer. (Dec 24;Volume 34, Issue 12).
doi: 10.1136/ijgc-2024-005976.

Jalid Sehouli, Jolijn Boer, Alison H Brand, Amit M Oza, Jennifer O’Donnell, Katherine Bennett, Ros Glaspool, Chee Khoon Lee, Josee-Lyne Ethier, Philipp Harter, Veronika Seebacher-Shariat, Ting-Chang Chang, Paul A Cohen, Toon van Gorp, Adriana Chavez-Blanco, Stephen Welch, Hanna Hranovska, Sharon O’Toole, Christianne A R Lok, Ainhoa Madariaga, Jose Alejandro Rauh-Hain, Alejandro Perez Fidalgo, David Tan, Judith Michels, Bhavana Pothuri, Noriko Fujiwara, Ora Rosengarten, Hiroshi Nishio, Se Ik Kim, Asima Mukherjee, Elisa Piovano, Sabrina Chiara Cecere, Elise C Kohn, Uma Mukherjee, Sara Nasser, Kristina Lindemann, Jennifer Croke, Xiaojun Chen, Franziska Geissler, Michael A Bookman. How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting
International Journal of Gynecological Cancer. (Nov 24;Volume 34, Issue 11).
doi: 10.1136/ijgc-2024-005982.

C.L. Scott, M.L. Friedlander, K. Francis, A.E.R. Kartikasari, K. Diamante, N. Bound, C. Davies, R. O’Connell, Y.C. Lee, J. Lombard, S.E. Baron-Hay, Y. Antill, C. Shannon, S. Selva-Nayagam, P.J. Beale, K. Shield-Artin, M. Wakefield, C. Vandenberg, M. Plebanski, C.K. Lee. 747P SOLACE2: A phase II randomized trial of olaparib (O) and durvalumab (D) with or without low dose cyclophosphamide (LDCy) in platinum-sensitive recurrent ovarian cancer (PSROC).
ESMO Annals of Oncology. (2024 Sep;35(Supplement 2):S566–S567).
doi: 10.1016/j.annonc.2024.08.808.

2024

Isabelle Ray-Coquard, Paolo Giovanni Casali, Sabrina Croce, Fiona M Fennessy, Fischerova, Robin Jones, Roberta Sanfilippo, Ignacio Zapardiel, Frédéric Amant, Jean-Yves Blay, Javier Martἰn-Broto, Antonio Casado, Sarah Chiang, Angelo Paolo Dei Tos, Rick Haas, Martee L Hensley, Peter Hohenberger, Jae-Weon Kim, Se Ik Kim, Mehmet Mutlu Meydanli, Patricia Pautier, Albiruni R Abdul Razak, Jalid Sehouli, Winan van Houdt, François Planchamp and Michael Friedlander. ESGO/EURACAN/GCIG guidelines for the management of patients with uterine sarcomas. International Journal of Gynaecological Oncology (BMJ) Vol 34/issue 10. https://doi.org/10.1016/S1470-2045(24)00334-6

Nicoletta Colombo, Elena Biagioli, Kenichi Harano, Francesca Galli, Emma Hudson, Yoland Antill, Chel Hun Choi, Manuela Rabaglio, Frederic Marmé, Christian Marth, Gabriella Parma, Lorena Fariñas-Madrid, Shin Nishio, Karen Allan, Yeh Chen Lee, Elisa Piovano, Beatriz Pardo, Satoshi Nakagawa, John McQueen, Claudio Zamagni, Luis Manso, Kazuhiro Takehara, Giulia Tasca, Annamaria Ferrero, Germana Tognon, Andrea Alberto Lissoni, Mariacristina Petrella, Maria Elena Laudani, Eliana Rulli, Sara Uggeri, M Pilar Barretina Ginesta, and AtTEnd study group*. Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Oncol. Sep 2024. https://doi.org/10.1016/S1470-2045(24)00334-6

Yeh Chen Lee, Tara Castellano, Tashanna K. N. Myers, Elizabeth H Barnes, Dana Meredith Chase, Colleen McCormick, Katrina Diamante, Catherine M. Shannon, Warner King Huh, Jayanthi Sivasothy Lea, Joan L. Walker, William Small Jr., Katherine Miller, Geetha Govindarajulu, Bradley J. Monk, Martin R Stockler, Kathleen N. Moore, Linda R. Mileshkin, and Victoria Lin Bae-Jump. Racial disparities and survival outcome of patients with locally advanced cervix cancer in the international randomised phase 3 OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274). J Gynecol Oncol. 2024 Jul;35(4):e111. doi: 10.3802/jgo.2024.35.e111. PMID: 39032926; PMCID: PMC11262895.

Olawaiye AB, Kim JW, Bagameri A, Bishop E, Chudecka-Głaz A, Devaux A, Gladieff L, Gordinier ME, Korach J, McCollum ME, Mileshkin L, Monk BJ, Nicum S, Nogueira-Rodrigues A, Oaknin A, O’Malley DM, Orlando M, Dreiling L, Tudor IC, Lorusso D. Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer. J Gynecol Oncol. 2024 Jul;35(4):e111. doi: 10.3802/jgo.2024.35.e111. PMID: 39032926; PMCID: PMC11262895.

Chen Lee Y, Castellano T, K. N. Myers T, H Barnes E, Meredith Chase D, McCormick C, Diamante K, M. Shannon C, King Huh W, Sivasothy Lea J, L. Walker J, Small Jr., Katherine Miller W, Govindarajulu G, J. Monk B, R Stockler M, N. Moore K, Mileshkin L, Lin Bae-Jump V. Racial disparities and survival outcome of patients with locally advanced cervix cancer in the international randomised phase 3 OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274). 2024, May 29. doi: https://ascopubs.org/doi/abs/10.1200/JCO.2024.42.16_suppl.1594?cookieSet=1

Werner B, Sjoquist KM, Espinoza D, Yip S, Chang G, Cummins MM, Mileshkin L, Ananda S, Shannon C, Friedlander M, Warton K, Ford CE.Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial. Transl Oncol. 2024 Feb 27;43:101914. doi: 10.1016/j.tranon.2024.101914

Roncolato F, King M, O’Connell R, Chen Lee Y, Joly F, Hilperti F, Lanceley A, Yoshida Y, Bryce J, Donnellan P, Oza A, Avall-Lundqvist E, Berek J, Ledermann J, Bertong D, Sehouli J, Kaminsky M, Stockler M, Friedlander M, Hidden in plain sight – Survival consequences of baseline symptom burden in women with recurrent ovarian cancer. 2024 February 26. DOI:https://doi.org/10.1016/j.ygyno. 2024.02.025

Rajadevan N, Flinkier A, Saunders H, Chen Lee Y, Scott C, Khaw P, Allan P, Davies C, Andrews J, Wilson M, Lombard J M, Harrison M, Nesfield H, DeFazio A, Meniawy T, Gorringe K L, Mucinous ovarian carcinoma: A survey of practice in Australia and New Zealand. 2024 Feb 1. doi: 10.1111/ajo.13792 [https://pubmed.ncbi.nlm.nih.gov/38299485/

Kaya M, Post CCB, Tops CM, Nielsen M, Crosbie EJ, Leary A, Mileshkin LR, Han K, Bessette P, de Boer SM, Jürgenliemk-Schulz IM, Lutgens L, Jobsen JJ, Haverkort MAD, Nout RA, Kroep J, Creutzberg CL, Smit VTHBM, Horeweg N, van Wezel T, Bosse T. Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter Hypermethylation. Mod Pathol. 2024 Jan 6:100423. doi: 10.1016/j.modpat.2024.100423. Epub ahead of print. PMID: 38191122. [https://pubmed.ncbi.nlm.nih.gov/38191122/]

2023

Nohová I, Andrews J, Votan B, Miller A, Sehouli J, Berger R. Patient involvement in research within the Gynecological Cancer InterGroup: A call to action for a systematic approach: Results from a survey. 03 Dec 2023, DOI: https://doi.org/10.1002/hsr2.1735. [https://onlinelibrary.wiley.com/doi/10.1002/hsr2.1735]

Mileshkin L, Narayan K, Gaffney D, Barnes E, Lee Y, Monk B, Stockler M. Adjuvant chemotherapy for locally advanced cervical cancer – Authors’ reply. 2023, Jul DOI:https://doi.org/10.1016/S1470-2045(23)00294-2

Lindemann K, Liland H, Donner M, Brew S, Lee Y, Vistad I, Nilsen E, Lombard J, Mirza,M, Madsen K, Hansson A, Andrews J, Campbell, R, Davis A. GCIG SB-001/NSGO-CTU-PEACE/ANZGOG 1923/2020: Palliation in gynae-oncology—Patients’ expectations and assessment of care. 2023 31 May DOI: 10.1200/JCO.2023.41.16_suppl.TPS5635 Journal of Clinical Oncology 41, no. 16_suppl (June 01, 2023) [TPS5635-TPS5635.https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.TPS5635]

Buchanan Daniel, Mahmood K, Georgeson P, Walker R, Robledo K, Cummins M, Spurdle A, Smith D, Joo E, Clendenning M, Como J, Preston S, Yip S, Andrews J, Kok P, Lee Y, Stockler M, Mileshkin L, Antill Y, Australia New Zealand Gynaeocological Oncology Group (ANZGOG). The impact of cause of mismatch repair deficiency and other molecular markers on clinical outcomes with the use of durvalumab in advanced endometrial cancer in the phase 2 PHAEDRA trial (ANZGOG1601).2023 31 May DOI: 10.1200/JCO.2023.41.16_suppl.5604 Journal of Clinical Oncology 41, no. 16_suppl (June 01, 2023) 5604-5604. [https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.5604]

Werner B, Sjoquist K, Espinoza D, Yip S, Chang G, Cummins M, Mileshkin L, Ananda S, Shannon C, Friedlander M, Warton K, Ford C. Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response: A translational sub-study of the REZOLVE (ANZGOG-1101) clinical trial. 2023 31 May DOI: 10.1200/JCO.2023.41.16_suppl.5561 Journal of Clinical Oncology 41, no. 16_suppl (June 01, 2023) 5561-5561. [https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.5561]

Sjoquist K, Dobrovic A Robledo K, Baron-Hay Sally, Ananda S, McCarthy N, Goh J, Murray N, Steer C, Yip S, Mileshkin L, Kondrashova O, Fink L, Chang G, Bailey L, Lee Y, Zebic Danka, Vandenberg C, Scott C, Waring P. Olaparib in HR-deficient (HRD), metastatic triple-negative breast cancer (TNBC) and relapsed ovarian cancer (ROC) without germline mutations in BRCA1 or BRCA2: Phase 2 EMBRACE trial. 2023 31 May DOI: 10.1200/JCO.2023.41.16_suppl.e15079 Journal of Clinical Oncology 41, no. 16_suppl (June 01, 2023) e15079-e15079 [https://ascopubs.org/doi/pdf/10.1200/JCO.2023.41.16_suppl.e15079?role=tab]

Dall G, Vandenberg C, Nesic K, Ratnayake G, Zhu W, Vissers W, Bedő J, Penington J, Wakefield M, Damien Kee, Carmagnac A, Lim R, Shield-Artin K, Milesi B, Lobley A, Kyran E, O’Grady E, Tram J, Zhou W, Nugawela D, Stewart K, Caldwell R, Papadopoulos L, Ng A, Dobrovic A, Fox S, McNally O, Power J, Meniawy T, Han Tan T, Collins I, Klein O, Barnett S, Olesen I, Hamilton A, Hofmann O, Grimmond S, Papenfuss A, Scott C, Barker H. Targeting homologous recombination deficiency in uterine leiomyosarcoma. 2023 4May , DOI: https://doi.org/10.1186/s13046-023-02687-0 https://jeccr.biomedcentral.com/articles/10.1186/s13046-023-02687-0#citeas

Mileshkin L, Moore K, Barnes E, Gebski V, Narayan K, King M, Bradshaw N, Lee Y, Diamante K, Fyles A, Small W, Gaffney D, Khaw P, Brooks S, Thompson S, Huh W, Mathews C, Buck M, Suder A, Lad T, Barani I, Holschneider C, Van Dyk S, Quinn M, Rischin D, Bradley M, Stockler M. Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial. 2023 17 April. DOI:https://doi.org/10.1016/S1470-2045(23)00147-X

Hayes S, Obermair A, Mileshkin L, Davis A, Gordon L, Eakin E, Janda M, Beesley V, Barnes E, Spence R, Sandler C, Jones T, Vagenas D, Webb P, Andrews J, Brand A, Chen Y, Friedlander M, Pumpa K, O’Neille H, Williams M, Stockler M. The ECHO Collaborative, Exercise during Chemotherapy for Ovarian cancer (ECHO) trial: design and implementation of a randomised controlled trial. BMJ Open. 2023 13 Apr ;13(4):e067925. doi: 10.1136/bmjopen-2022-067925 https://bmjopen.bmj.com/content/13/4/e067925

Tan D, Fujiwara N, Fujiwara K, Beale P, Kim JW, Ng J, Kim SI, Evans A, Kim BG; Asia-Pacific Gynecologic Oncology Trials Group (APGOT). The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women’s cancer research organization. J Gynecol Oncol. 2023 Mar;34(2):e33. doi: 10.3802/jgo.2023.34.e33. PMID: 36890293; PMCID: PMC9995874. [https://pubmed.ncbi.nlm.nih.gov/36890293/]

2022

Smith D, Robledo KP, Yip S, Cummins MM, Kok PS, Lee YC, Friedlander M, Baron-Hay S, Shannon C, Coward J, Beale P, Goss G, Meniawy T, Lombard J, Spurdle AB, Andrews J, Stockler MR, Mileshkin L, Antill Y; Australia New Zealand Gynaecological Oncology Group (ANZGOG). Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA). Cancers (Basel). 2022 Dec 30;15(1):254. doi: 10.3390/cancers15010254. PMID: 36612250; PMCID: PMC9818816 [https://pubmed.ncbi.nlm.nih.gov/36612250/]

You B, Sehgal V, Hosmane B, Huang X, Ansell PJ, Dinh MH, Bell-McGuinn K, Luo X, Fleming GF, Friedlander M, Bookman MA, Moore KN, Steffensen KD, Coleman RL, Swisher EM. CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study. J Clin Oncol. 2023 Jan 1;41(1):107-116. doi: 10.1200/JCO.22.00430. Epub 2022 Jul 22. PMID: 35867965 [https://pubmed.ncbi.nlm.nih.gov/35867965/]

Fremond S, Andani S, Barkey Wolf J, Dijkstra J, Melsbach S, Jobsen JJ, Brinkhuis M, Roothaan S, Jurgenliemk-Schulz I, Lutgens LCHW, Nout RA, van der Steen-Banasik EM, de Boer SM, Powell ME, Singh N, Mileshkin LR, Mackay HJ, Leary A, Nijman HW, Smit VTHBM, Creutzberg CL, Horeweg N, Koelzer VH, Bosse T. Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts. Lancet Digit Health. 2022 Dec 7:S2589-7500(22)00210-2. doi: 10.1016/S2589-7500(22)00210-2. Epub ahead of print. PMID: 36496303. (https://pubmed.ncbi.nlm.nih.gov/36496303/)

D SP Tan, CH Choi4, N YL Ngoi, H Sun, V Heong, S GW Ow, W Y Chay, H S Kim, G Goss, J C Goh, Vilianty, B C Tai, D GZ Lim, N Kaliaperumal, V B Au, J E Connolly, Jae-Weon Kim, M Friedlander, K Kim. A Multicenter Phase II Randomized Trial of Durvalumab (D) Versus Physician’s Choice Chemotherapy (PCC) in Patients (pts) with Recurrent Ovarian Clear Cell Carcinoma (MOCCA/ APGOT-OV2/ GCGS-OV3/GCIG). ASCO Annual Meeting 2022. (https://www.anzgog.org.au/wp-content/uploads/2022/12/ASCO2022_MOCCA_FINALresized.pdf)

H Woopen, J Sehouli, A Davis, Y C Lee, P A Cohen, A Ferrero, N Gleeson, A Jhingran, Y Kajimoto, J Mayadev, M P Barretina-Ginesta, S Sundar, N Suzuki, E van Dorst, F Joly. Erratum to “GCIG-Consensus guideline for long-term survivorship in gynecologic cancer: A position paper from the Gynecologic Cancer InterGroup (GCIG) symptom benefit committee” [Cancer Treatm. Rev. 107 (2022) 102396]. DOI: 10.1016/j.ctrv.2022.102431. Epub 2022 May 2. Cancer Treat Rev. 2022. PMID: 35525106 Review. (https://pubmed.ncbi.nlm.nih.gov/35803179/#article-details)

L R. Mileshkin, K N. Moore, E Barnes, Y Chen Lee, V Gebski, K Narayan, N Bradshaw, K Diamante, A W. Fyles, W Small, D K. Gaffney, P Khaw, S Brooks, J S. Thompson, W King Huh, M Carlson, K Robinson, D Rischin, M R. Stockler, B J. Monk. Staging locally advanced cervical cancer with FIGO 2018 versus FIGO 2008: Impact on overall survival and progression-free survival in the OUTBACK trial. DOI: 10.1200/JCO.2022.40.16_suppl.5531 Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) 5531-5531. Published online June 02, 2022. (https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.5531)

Campbell R, Costa DSJ, Stockler MR, Lee YC, Ledermann JA, Berton D, Sehouli J, Roncolato FT, Connell RO, Okamoto A, Bryce J, Oza AM, Avall-Lundqvist E, Berek JS, Lanceley A, Joly F, Hilpert F, Feeney A, Kaminsky MC, Diamante K, Friedlander ML, King MT; GCIG Symptom Benefit Group. Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer. Gynecol Oncol. 2022 Aug;166(2):254-262. doi: 10.1016/j.ygyno.2022.05.024. Epub 2022 Jun 17. PMID: 35718565. (https://pubmed.ncbi.nlm.nih.gov/35718565/)

Andrew R Clamp, Elizabeth C James, Iain A McNeish, Andrew Dean, Jae-Won Kim, Dearbhaile M O’Donnell, et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2022 Jul;23(7):919-930. doi: 10.1016/S1470-2045(22)00283-2. Epub 2022 Jun 9. PMID: 35690073.(https://pubmed.ncbi.nlm.nih.gov/35690073/)

Lee YC, King MT, O’Connell RL, Lanceley A, Joly F, Hilpert F, Davis A, Roncolato FT, Okamoto A, Bryce J, Donnellan P, Oza AM, Avall-Lundqvist E, Berek JS, Ledermann JA, Berton D, Sehouli J, Feeney A, Kaminsky MC, Diamante K, Stockler MR, Friedlander ML; GCIG Symptom Benefit Group. Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study. Int J Gynecol Cancer. 2022 Jun 6;32(6):761-768. doi: 10.1136/ijgc-2021-003142. PMID: 35086926. (https://pubmed.ncbi.nlm.nih.gov/35086926/)

Woopen H, Sehouli J, Davis A, Lee YC, Cohen PA, Ferrero A, Gleeson N, Jhingran A, Kajimoto Y, Mayadev J, Barretina-Ginesta MP, Sundar S, Suzuki N, van Dorst E, Joly F. GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: A position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee. Cancer Treat Rev. 2022 Jun;107:102396. doi: 10.1016/j.ctrv.2022.102396. Epub 2022 May 2. PMID: 35525106 Review. (https://pubmed.ncbi.nlm.nih.gov/35525106/)

A Obermair, O McNally, R Farrell, R Ribeiro, JSY Ng. Are endometrial cancer clinical practice management guidelines sufficiently consumer centric? Int J Gynecol Cancer: first published as 10.1136/ijgc-2022-003580 on 27 April 2022. (https://ijgc.bmj.com/content/ijgc/early/2022/04/26/ijgc-2022-003580.full.pdf)

Aghajanian C, Swisher EM, Okamoto A, Steffensen KD, Bookman MA, Fleming GF, Friedlander M, Moore KN, Tewari KS, O’Malley DM, Chan JK, Ratajczak C, Hashiba H, Wu M, Dinh MH, Coleman RL. Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer – an ancillary data analysis of the VELIA trial. Gynecol Oncol. 2022 Feb;164(2):278-287. doi: 10.1016/j.ygyno.2021.12.012. Epub 2021 Dec 18. PMID: 34930617 Clinical Trial. (https://pubmed.ncbi.nlm.nih.gov/34930617/)

Swisher EM, Aghajanian C, O’Malley DM, Fleming GF, Kaufmann SH, Levine DA, Birrer MJ, Moore KN, Spirtos NM, Shahin MS, Reid TJ, Friedlander M, Steffensen KD, Okamoto A, Sehgal V, Ansell PJ, Dinh MH, Bookman MA, Coleman RL. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecol Oncol. 2022 Feb;164(2):245-253. doi: 10.1016/j.ygyno.2021.12.003. Epub 2021 Dec 11. PMID: 34906376 Clinical Trial. (https://pubmed.ncbi.nlm.nih.gov/34906376/)

Beesley VL, Ross TL, King MT, Campbell R, Nagle CM, Obermair A, Grant P, DeFazio A, Webb PM, Friedlander ML; OPAL Study Group. Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns). Gynecol Oncol. 2021 Dec 23:S0090-8258(21)01632-2. doi: 10.1016/j.ygyno.2021.12.006. Epub ahead of print. PMID: 34955238. (https://pubmed.ncbi.nlm.nih.gov/34955238/)

Aghajanian C, Swisher EM, Okamoto A, Steffensen KD, Bookman MA, Fleming GF, Friedlander M, Moore KN, Tewari KS, O’Malley DM, Chan JK, Ratajczak C, Hashiba H, Wu M, Dinh MH, Coleman RL. Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer – an ancillary data analysis of the VELIA trial. Gynecol Oncol. 2021 Dec 17:S0090-8258(21)01638-3. doi: 10.1016/j.ygyno.2021.12.012. Epub ahead of print. PMID: 34930617. (https://pubmed.ncbi.nlm.nih.gov/34930617/)

Swisher EM, Aghajanian C, O’Malley DM, Fleming GF, Kaufmann SH, Levine DA, Birrer MJ, Moore KN, Spirtos NM, Shahin MS, Reid TJ, Friedlander M, Steffensen KD, Okamoto A, Sehgal V, Ansell PJ, Dinh MH, Bookman MA, Coleman RL. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecol Oncol. 2021 Dec 11:S0090-8258(21)01630-9. doi: 10.1016/j.ygyno.2021.12.003. Epub ahead of print. PMID: 34906376. (https://pubmed.ncbi.nlm.nih.gov/34906376/)

Khaw P, Do V, Lim K, Cunninghame J, Dixon J, Vassie J, Bailey M, Johnson C, Kahl K, Gordon C, Cook O, Foo K, Fyles A, Powell M, Haie-Meder C, D’Amico R, Bessette P, Mileshkin L, Creutzberg CL, Moore A. Radiotherapy Quality Assurance in the PORTEC-3 (TROG 08.04) Trial. Clin Oncol (R Coll Radiol). 2022 Mar;34(3):198-204. doi: 10.1016/j.clon.2021.11.015. Epub 2021 Dec 11. PMID: 34903431. (https://pubmed.ncbi.nlm.nih.gov/34903431/).

A Obermair, J Nicklin, V Gebski, S C. Hayes, N Graves, L Mileshkin, M Y. Lin, P Beale, E Baxter, K Robledo, C Salomon, G B. Hanna, M Janda. A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer – ENDO-3: ANZGOG trial 1911/2020. International Journal of Gynecologic Cancer, Nov 2021, doi:10.1136/ijgc-2021-003029, (https://pubmed.ncbi.nlm.nih.gov/34728527/)

R Farrell, M Burling, Y Chen Lee, S Pather, K Robledo, R Mercieca-Bebber, M Stockler, and on behalf of the HyNOVA Protocol Steering Committee. Clinical Trial Protocol for HyNOVA: Hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial OVArian, fallopian tube and primary peritoneal cancer (ANZGOG1901/2020). Journal of Gynecologic Oncology. 2022 Jan;33(1):e1. doi:org/10.3802/jgo.2022.33.e1. Epub 2021 Oct 18. PMID: 34783204. (https://pubmed.ncbi.nlm.nih.gov/34783204/)

A Obermair, P Beale, C L. Scott, V Beshay, G Kichenadasse, B Simcock, J Nicklin, Y Chen-Lee, P Cohen, T Meniawy. Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020. Journal of Gynecologic Oncology, Oct 12, 2021, doi: org/10.3802/jgo.2021.32.e95, (https://ejgo.org/DOIx.php?id=10.3802/jgo.2021.32.e95)

R J. Edmondson, R L. O’Connell, S Banerjee, L Mileshkin, P Sykes, P Beale, A Fisher, A Bonaventura, D Millan, S Nottley, C Benson, A Hamilton, K Sjoquist, L Alexander, C Kelly, K Carty, L Divers, N Bradshaw, M Friedlander, PARAGON investigators. Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903). Gynecologic Oncology, 2021 December;163(3)524-530. doi: 10.1016/j.ygyno.2021.09.010. Epub 2021 Oct 5. PMID: 34625284. (https://pubmed.ncbi.nlm.nih.gov/34625284/)

Banerjee SN, Tang M, O’Connell RL, Sjoquist K, Clamp AR, Millan D, Nottley S, Lord R, Mullassery VM, Hall M, Gourley C, Bonaventura T, Goh JC, Sykes P, Grant PT, McNally O, Alexander L, Kelly C, Carty K, Divers L, Bradshaw N, Edmondson RJ, Friedlander M; PARAGON investigators. A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial. Gynecol Oncol. 2021 Oct;163(1):72-78. doi: 10.1016/j.ygyno.2021.07.024. Epub 2021 Aug 16. PMID: 34412908. (https://pubmed.ncbi.nlm.nih.gov/34412908/)

B G. Wortman, C CB. Post, M E. Powell, P Khaw, A Fyles, R D’Amico, C Haie-Meder, I M. Jürgenliemk-Schulz, M McCormack, V Do, D Katsros, P Bessette, M H. Baron, R A Nout, K Whitemarsh, L Mileshkin, L CHW. Lutgens, H C. Kitchener, S Brooks, Nijman HW, E Astreinidou, H Putter, C L. Creutzberg, S M. de Boer. Radiotherapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of Three-Dimensional Conformal Radiotherapy versus Intensity-Modulated Radiotherapy. International Journal of Radiation Oncology Biology Physics. 2022 Feb 1;112(2):390-399. doi: 10.1016/j.ijrobp.2021.09.042. Epub 2021 Oct 2. PMID: 34610387. (https://pubmed.ncbi.nlm.nih.gov/34610387/)

P Cohen, P M. Webb, M King, A Obermair, V Gebski, P Butow, R Morton, W Lawson, P Yates, R Campbell, T Meniawy, M McMullen, A Dean, J Goh, O McNally, L Mileshkin, P Beale, R Beach, J Hill, C Dixon, S Hegarty, J Codde, A Ives, Y Chen Lee, A Brand, A Mellon, S Bilic, I Black, S Jeffares, M Friedlander. Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer. International Journal of Gynecologic Cancer, Sep 22, 2021, doi: 10.1136/ijgc-2021-002999, (https://ijgc.bmj.com/content/early/2021/09/21/ijgc-2021-002999)

R Campbell, M T. King, T L. Ross, P A. Cohen, M Friedlander, P Webb. Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment. National Library of Medicine, Sep 2021, 1:S0090-8258(21)01320-2, https://doi.org/10.1016/j.ygyno.2021.08.022. (https://pubmed.ncbi.nlm.nih.gov/34481610/)

M Hickey, K M. Moss, E O. Krejany, C D. Wrede, S M. Domchek, J Kirk, A Brand, A Trainer, G D. Mishra, F C. Baker. What happens after menopause? (WHAM): A prospective controlled study of sleep quality up to 12 months after premenopausal risk-reducing salpingo-oophorectomy. Gynecologic Oncology, Volume 162, Issue 2, P447-453, August 01, 2021, doi.org/10.1016/j.ygyno.2021.05.036

M Hickey, K M. Moss, E O. Krejany, C D. Wrede, A Brand, J Kirk, H L. Symeck, S M. Domcheck, T Tejada-Berges, A Trainer, G D. Mishra. What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 12 months after premenopausal risk-reducing salpingo-oophorectom. Gynecologic Oncology, Volume 162, Issue 2, P447-453, August 01, 2021, doi.org/10.1016/j.ygyno.2021.07.029

R M. Islam, S R. Davis, R J. Bell, T Tejada-Berges, C D. Wrede, S M, Domchek, B Meiser, J Kirk, E O. Krejany, M Hickey. A prospective controlled study of sexual function and sexually related personal distress up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy. Menopause: The Journal of The North American Menopause Society, Volume 28, No. 7, 748-755, July, 2021 doi: 10.1097/gme.0000000000001766 (A prospective controlled study of sexual function and sexual… : Menopause (lww.com)

L R. Mileshkin, K N. Moore, E Barnes, V Gebski, K Narayan, N Bradshaw, Y Chen Lee, K Diamante, A W. Fyles, W Small, D K. Gaffney, P Khaw, S Brooks, J S. Thompson, W King Huh, M Carlson, C A. Matthews, D Rischin, M R. Stockler, B J. Monk. Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274). Journal of Clinical Oncology, Volume 39, Issue 18, June 2021, doi: 10.1200/JCO.2021.39.15_suppl.LBA3. (https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.LBA3).

M Hickey, K M. Moss, G D. Mishra, E O. Krejany, S M. Domchek, J D. Wark, A Trainer, R A. Wild. What Happens After Menopause? (WHAM): A prospective controlled study of cardiovascular and metabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy. Gynecologic Oncology, 2021, ISSN 0090-8258, https://doi.org/10.1016/j.ygyno.2021.04.038 (https://www.sciencedirect.com/science/article/pii/S0090825821003589)

M Hickey, K.M. Moss, A Brand, C.D. Wrede, S.M. S. Domchek, B Meiser, G Mishra, H Joffe (2021). What happens after menopause? (WHAM): A prospective controlled study of depression and anxiety up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy. Gynecologic Oncology. 161. 10.1016/j.ygyno.2021.02.001.

Vermij L, Horeweg N, Leon-Castillo A, Rutten TA, Mileshkin LR, Mackay HJ, Leary A, Powell ME, Singh N, Crosbie EJ, Smit VTHBM, Creutzberg CL, Bosse T. HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes. Cancers (Basel). 2020 Dec 25;13(1):44. doi: 10.3390/cancers13010044. PMID: 33375706; PMCID: PMC7795222.

Elyashiv O, Ledermann J, Parmar G, Farrelly L, Counsell N, Feeney A, El-Khouly F, Macdonald I, Neto A, Arthur-Darkwa E, Burnett E, C Jayson G, Mileshkin L, Gourley C, and Nicum S. ICON 9—an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy. International Journal of Gynecologic Cancer Published Online First: 23 October 2020. doi: 10.1136/ijgc-2020-002073.

Paul A. Cohen, Yee Leung, Lyndal Anderson, Rachael van der Griend, Paola Chivers, Sanela Bilic, Sophie Bittinger, Alison Brand, Max K. Bulsara, Jim Codde, Lois Eva, Louise Farrell, Dianne Harker, Unine Herbst, Stephanie Jeffares, Diane Loh, Orla McNally, Ganendra Raj Mohan, Tarryn Nicholson, Aime Powell, Stuart G. Salfinger, Bryony Simcock, Colin Stewart, Julie Silvers, Martin R. Stockler, Peter Sykes, Pennie Stoyles, Adeline Tan, Ai Ling Tan, C. David H. Wrede. Excisional treatment comparison for in situ endocervical adenocarcinoma (EXCISE): A phase 2 pilot randomized controlled trial to compare histopathological margin status, specimen size and fragmentation after loop electrosurgical excision procedure and cold knife cone biopsy. Gynecologic Oncology, 2020, ISSN 0090-8258, https://doi.org/10.1016/j.ygyno.2020.09.053.

P. Schofield, K. Gough, M. Pascoe, R. Bergin, K. White, L. Mileshkin, D. Bernshaw, N. Kinnane, M. Jackson, V. Do, A. Brand, S. Aranda, R. Cheuk, A. Drosdowsky, S. Penberthy, I. Juraskova. A nurse- and peer-led psycho-educational intervention to support women with gynaecological cancers receiving curative radiotherapy: The PeNTAGOn randomised controlled trial – ANZGOG 1102. Gynecologic Oncology, Available online 19 September 2020. https://doi.org/10.1016/j.ygyno.2020.09.016

Norell CH, Butler J, Farrell R, Altman A, Bentley J, Cabasag CJ, Cohen PA, Fegan S, Fung-Kee-Fung M, Gourley C, Hacker NF, Hanna L, Høgdall CK, Kristensen G, Kwon J, McNally O, Nelson G, Nordin A, O’Donnell D, Schnack T, Sykes PH, Zotow E, Harrison S. Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care. International Journal of Gynecologic Cancer Published Online First: 11 August 2020. doi: 10.1136/ijgc-2020-001403

León-Castillo A, de Boer SM, Powell ME, Mileshkin L, Mackay H, Leary A, Nijman HW, Singh N, Pollock PM, Bessette B, Fyles A, Haie-Meder C, Smit VTHBM, Edmondson RJ, Putter H, Kitchener HC, Crosbie EJ, de Bruyn M, Nout RA, Horeweg N, Creutzberg CL; and Bosse T. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. Journal of Clinical Oncology: Published online August 04, 2020. doi: 10.1200/JCO.20.00549

Obermair A, Baxter E, Brennan DJ, MD, McAlpine JN, Mueller JJ, Amant F, van Gent MDJM, Coleman RL, Westin SN, Yates MS, Krakstad C, Janda M. Fertility-sparing treatment in early endometrial cancer: current state and future strategies. Obstetrics and Gynecology Science: Vol. 63, No. 4, 2020. https://doi.org/10.5468/ogs.19169

Natalie YL Ngoi, Valerie Heong, Samuel Ow, Wen Yee Chay, Hee Seung Kim, Chel Hun Choi, Geraldine Goss, Jeffrey C Goh, Bee Choo Tai, Diana GZ Lim, Nivashini Kaliaperumal, Veonice B Au, John E Connolly, Jae-Weon Kim, Michael Friedlander, Kidong Kim, David SP Tan.A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA). Int J Gynecol Cancer.Published Online First: 25 June 2020. doi: 10.1136/ijgc-2020-001604

C. Uwins, GP. Bhandoria, TS. Shylasree, S. Butler-Manuel, P. Ellis, Jayanta Chatterjee, A. Tailor, A. Stewart, A. Michael. COVID-19 and gynecological cancer: a review of the published guidelines. Int J Gynecol Cancer. Published Online First: [June 8 2020]. https://doi:10.1136/ijgc-2020-001634

L. M. Wiltink, M. King, F. Müller, M. S. Sousa, M. Tang, A. Pendlebury, J. Pittman, N. Roberts, L. Mileshkin, R. Mercieca-Bebber, M.-A. Tait, R. Campbell & C. Rutherford. A systematic review of the impact of contemporary treatment modalities for cervical cancer on women’s self-reported health-related quality of life. Support Care Cancer (2020). https://doi.org/10.1007/s00520-020-05554-2

T. Sivakumaran, L. Mileshkin, P. Grant, L. Na, A. DeFazio, M. Friedlander, A. Obermair, P.M. Webb, G. Au-Yeung. Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study. Gynecologic Oncology, 2020, ISSN 0090-8258 – https://doi.org/10.1016/j.ygyno.2020.04.706 (http://www.sciencedirect.com/science/article/pii/S0090825820310167)

Jacobus Pfisterer, Catherine M Shannon, Klaus Baumann, Joern Rau, Philipp Harter, Florence Joly, Jalid Sehouli, Ulrich Canzler, Barbara Schmalfeldt, Andrew P Dean, Alexander Hein, Alain G Zeimet, Lars C Hanker, Thierry Petit, Frederik Marmé, Ahmed El-Balat, Rosalind Glasspool, Nikolaus de Gregorio, Sven Mahner, Tarek M Meniawy, Tjoung-Won Park-Simon, Marie-Ange Mouret-Reynier, Cristina Costan, Werner Meier, Alexander Reinthaller, Jeffrey C Goh, Tifenn L’Haridon, Sally Baron Hay, Stefan Kommoss, Andreas du Bois, Jean-Emmanuel Kurtz, Sven Ackermann, Christoph Anthuber, Mustafa Aydogdu, Angelika Baldauf, Wolfgang Bauer, Dirk Behringer, Antje Belau, Alexandra Bender, Cosima Brucker, Alexander Burges, Ulrich Canzler, Trygve Daabach, Dominik Denschlag, Mustafa Deryal, Steffen Dörfel, Juliane Ebert, Ahmed El-Balat, Tanja Fehm, Susanne Maria Feidicker, Gabriele Feisel-Schwickardi, Ricardo Felberbaum, Matthias Frank, Gerhard Gebauer, Bernd Gerber, Axel Gerhardt, Andrea Grafe, Martin Griesshammer, Eva-Maria Grischke, Isolde Gröll, Martina Gropp-Meier, Dietrich Hager, Volker Hanf, Carla Verena Hannig, Peer Hantschmann, Philipp Harter, Tanja Hauzenberger, Uwe Herwig, Martin Heubner, Carsten Hielscher, Felix Hilpert, Thomas Hitschold, Manfred Hofmann, Christian Jackisch, Wolfgang Janni, Ludwig Kiesel, Yon-Dschun Ko, Hans-Joachim Koch, Petra Krabisch, Peter Krieger, Thomas Kubin, Thorsten Kühn, Björn Lampe, Peter Ledwon, Sabine Lemster, Benno Lex, Clemens Liebrich, Ralf Lorenz, Hans-Joachim Lück, Sven Mahner, Peter Mallmann, Frederik Marmé, Werner Meier, Wolfgang Meinerz, Götz Menke, Volker Möbus, Thomas Müller, Volker Müller, Tanja Neunhöffer, Angelika Ober, Gülten Oskay-Özcelik, Horst Ostertag, Tjoung-Won Park-Simon, Martin Pölcher, Beate Rautenberg, Daniel Rein, Wilhelm Reiter, Andreas Rempen, Ingo Runnebaum, Barbara Schmalfeldt, Marcus Schmidt, Sabine Schnohr, Heinz Scholz, Willibald Schröder, Jalid Sehouli, Eike Simon, Antje Sperfeld, Annette Steckkönig, Hans-Georg Strauß, Ronaldo Stuth, Jürgen Terhaag, Falk Thiel, Marc Thill, Oliver Tomé, Christoph Uleer, Susanne Vogel, Hermann Voß, Michael Weigel, Ulrich Winkler, Arthur Wischnik, Tobias Zeiser, Andreas Zorr, Ros Glasspool, Emma Hudson, Rachel Jones, Judith Lafleur, Christian Marth, Edgar Petru, Alexander Reinthaller, Yoland Antill, Mary Azer, Sally Baron-Hay, Philip Beale, Stephen Begbie, Allison Black, Karen Briscoe, Andrew Dean, Jeffrey Goh, Sandra Harvey, Chee Lee, Marco Matos, Tarek Meniawy, Inger Olesen, Catherine Shannon, Paul Vasey, Sophie Abadie-Lacourtoisie, Olivier Arsene, Sophie Barthier, Célia Becuwe-Roemer, Dominique Berton-Rigaud, Maria Cappiello-Bataller, Stéphanie Catala, Cristina Costan, Francesco Del Piano, Gaël Deplanque, Raymond Despax, Nadine Dohollou, Claire Garnier-Tixidré, Julien Grenier, Emmanuel Guardiola, Anne-Claire Hardy-Bessard, Florence Joly, Jean-Emmanuel Kurtz, Claudia Lefeuvre-Plesse, Marianne Leheurteur, Anne Lesoin, Charles-Briac Levache, Tifenn L’Haridon, Raffaele Longo, Alain Lortholary, Jérôme Meunier, Marie-Ange Mouret-Reynier, Thierry Petit, Nadia Raban, Olivier Romano, Jean-Michel Vannetzel, Alain Zannetti. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. The Lancet Oncology 2020. ISSN 1470-2045, https://doi.org/10.1016/S1470-2045(20)30142-X.

Cook O, McIntyre M, Recoche K, Lee S. A clearer pathway—The future of the gynaecological oncology specialist nurse role. Collegian: Journal of the Royal College of Nursing Australia: 15 January 2020. https://doi.org/10.1016/j.colegn.2019.11.009

L Mileshkin*, R Edmondson*, R.L. O’Connell, K.M. Sjoquist, J Andrews, R Jyothirmayi, P Beale, T Bonaventura, J Goh, M Hall, A Clamp, J Green, R Lord, F Amant, L Alexander, K Carty, J Paul, J Scurry, D Millan, S Nottley, M Friedlander, on behalf of the PARAGON study (*joint first author). Phase 2 study of anastrozole in recurrent estrogen (ER) / progesterone (PR) positive endometrial cancer: The PARAGON trial – ANZGOG 0903. https://pubmed.ncbi.nlm.nih.gov/31130288/

Clamp AR, James EC, McNeish IA, Dean A, Kim JW, O’Donnell DM, Hook J, Coyle C, Blagden S, Brenton JD, Naik R, Perren T, Sundar S, Cook AD,  Gopalakrishnan GS, Gabra H, Lord R, Dark G, Earl HM, Hall M, Banerjee S, Glasspool RM, Jones R, Williams S, Swart AM, Stenning S, Parmar M, Kaplan R,  Ledermann JA. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet Oncology. November 29, 2019. https://doi.org/10.1016/S0140-6736(19)32259-7

Antill Y, Kok PS, Stockler MR, Robledo KP, Yip S, Parry M, Smith D, Spurdle A, Barnes L, Friedlander M, Baron-Hay S, Shannon C, Coward J, Beale P, Goss G, Meniawy T, Andrews J, Kelly M and Mileshkin L on behalf of Australia New Zealand Gynaecological Oncology Group (ANZGOG). Updated results of activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: the phase 2 PHAEDRA trial (ANZGOG1601). Presented at ESMO Asia 2019. https://www.anzgog.org.au/wp-content/uploads/2019/11/PHAEDRA-Abstract-ESMOASIA19_updated-07Oct2019_FINAL.pdf

Ashley s. Felix, Erin M. McLaughlin, Bette J. Caan, David E. Cohn, Garnet L. Anderson, Electra D. Paskett. Guideline‐concordant endometrial cancer treatment and survival in the Women’s Health Initiative Life and Longevity After Cancer study. First published 16 October 2019 https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.32740

Mileshkin L, Barnes E, Moore K N, Gebski V, King M, Narayan K, Kolodziej I K, Sjoquist K, Fyles A, Small W, Gaffney D, Quinn M,  Andrews J, Thompson D,  Huh W, Carlson M, Disilvestro P A, Rischin D, Stockler M R, Monk B J. Disparities starting adjuvant chemotherapy for locally advanced cervix cancer in the international, academic, randomised, phase III OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274). Annals of Oncology, Volume 30, Issue Supplement_5, October 2019, mdz250.060, https://doi.org/10.1093/annonc/mdz250.060

Tang M, L. O’Connell R, Amant F, Beale P, McNally O, M. Sjoquist K, Grant P, Davis A, Sykes P, Mileshkin L, Moujaber T, J. Kennedy C,  de Fazio A, Tan K, Antill Y, Goh J, Bonaventura T, Scurry J, Friedlander M. PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. Gynecologic Oncology, Volume 154, Issue 3, September 2019, Pages 531-538, ISSN 0090-8258. https://doi.org/10.1016/j.ygyno.2019.06.011

Lee YC, Lheureux S, Raza Mirza M, Oza A. Targeted Therapy in Management of Endometrial Cancer. Management of Endometrial Cancer pp 249-276. https://doi.org/10.1007/978-3-319-64513-1_18

Webber K, Carolus E, Mileshkin L, Sommeijer D, McAlpine J, Bladgen S, Coleman RL, Herzog TJ, Sehouli J, Nasser S, Inci G, Friedlander M. OVQUEST – Life after the diagnosis and treatment of ovarian cancer – An international survey of symptoms and concerns in ovarian cancer survivors. Gynecologic Oncology August 2019. https://doi.org/10.1016/j.ygyno.2019.08.009

Embleton-Thirsk A, Deane E, Townsend S, Farrelly L, Popoola B, Parker J, Rustin G, Sydes M, Parmar M, Ledermann J, Kaplan R. Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization application. SAGE Journals 2019 July: https://doi.org/10.1177%2F1740774519862528

de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder Christine, Ottevanger PB, Ledermann J, Khaw P, D’Amico R, Fyles A, Baron MH, Jurgenliemk-Schuz I, Kitchener H, Nijman H, Wilson G, Brooks S, Gribaudo S, Provencher D, Hanzen C, Kruitwagen R, Smit V, Singh N, Do V, Lissoni A, Nout R, Feeney A, Verhoeven-Adema K, Putter H, Creutzberg C. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncology, 2019 July: http://dx.doi.org/10.1016/S1470-2045(19)30395-X

Mileshkin L, Edmondson R, O’Connell R, Sjoquist K, Andrews J, Jyothirmayi R, Beale P, Bonaventura T, Goh J, Hall M, Clamp A, Green J, Lord R, Amant F, Alexander L, Carty K, Scurry J, Millan D, Nottley S, Friedlander M. Phase 2 study of anastrazole in recurrent estrogen (ER) / progesterone (PR) positive endometrial cancer: The PARAGON trial – ANZGOG 0903. Gynecologic Oncology, Vol 154, July 2019: https://doi.org/10.1016/j.ygyno.2019.05.007

Narayan, K. Patient selection for clinical trials in endometrial cancer patients. Gynaecologic Oncology. 2019 June; Vol 154 (pg 276-277). https://doi.org/10.1016/j.ygyno.2019.04.644

Kok P, Beale P, O’Connell RL., Grant P, Bonaventura T, Scurry J, Antill Y, Goh J, Sjoquist K, DeFazio A,Mapagu C, Amant F, Friedlander M. PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression. J Gynecol Oncol. 2019 May(5):e86. https://doi.org/10.3802/jgo.2019.30.e86

Lindemann K, Beale P, Rossi E, Goh J, Vaughan M, Tenney M, Martyn J, Sommeijer D, Inglesias J, Kremmidiotis G, Simpson J, Doolin E, Lavranos T, Leske A, Veillard A, Espinoza D, Stockler M, Rischin D. (ANZGOG-1103) Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse. Cancer Chemotherapy and Pharmacology, Vol 83. 2019 January: https://doi.org/10.1007/s00280-018-3706-5

Wilson, M.K., R. Mercieca-Bebber, and M. Friedlander, A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer. J Gynecol Oncol, September 2018. 29(5): https://www.ncbi.nlm.nih.gov/pubmed/30022641

Sjoquist, K.M., L.R. Mileshkin, S. Ananda, C.M. Shannon, D. Bowtell, S. Yip, D. Espinoza, J.C. Goh, M.L. Harrison, M. Plebanski, V. Gebski, M.R. Stockler, K. Livingstone, M. Tang, and M. Friedlander, REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal (IP) bevacizumab (bev) for recurrent ascites in advanced, chemotherapy-resistant, epithelial ovarian cancer (CR-EOC). Journal of Clinical Oncology,June 2018. 36(15_suppl): p. 10097-10097DOI: http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.10097

Beesley, V.L., D.D. Smith, C.M. Nagle, M. Friedlander, P. Grant, A. DeFazio, P.M. Webb, and O.S. Group, Coping strategies, trajectories, and their associations with patient-reported outcomes among women with ovarian cancer. Support Care Cancer, June 2018 DOI: https://link.springer.com/article/10.1007/s00520-018-4284-0

King MT, Stockler MR, O’Connell RL, Buizen L, Joly F, Lanceley A, Hilpert F, Okamoto A, Aotani E, Bryce J, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Sehouli J, Feeney A, Berton-Rigaud D, Costa DSJ, Friedlander ML; GCIG Symptom Benefit group. Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer. Qual Life Res. 2017 Dec 16. https://doi.org/10.1007/s11136-017-1729-8 [Epub ahead of print] PubMed PMID: 29248998.

de Boer SM, Wortman BG, Bosse T, Powell ME, Singh N, Hollema H, Wilson G, Chowdhury MN, Mileshkin L, Pyman J, Katsaros D, Carinelli S, Fyles A, McLachlin CM, Haie-Meder C, Duvillard P, Nout RA, Verhoeven-Adema KW, Putter H, Creutzberg CL, Smit VTHBM; PORTEC study group. Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer. Ann Oncol. 2017 Nov 27. https://doi.org/10.1093/annonc/mdx753 PubMed PMID: 29190319.

C.A. Hamilton, A. Miller, Y. Casablanca, N.S. Horowitz, B. Rungruang, T.C. Krivak, S.D. Richard, N. Rodriguez, M.J. Birrer, F.J. Backes, M.A. Geller, M. Quinn, M.J. Goodheart, D.G. Mutch, J.J. Kavanagh, G.L. Maxwell, M.A. Bookman, Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study, Gynecologic Oncology, Available online 28 November 2017, ISSN 0090-8258, https://doi.org/10.1016/j.ygyno.2017.11.018

M A Bookman, A Okamoto, G Stuart, N Yanaihara, D Aoki, M Bacon, K Fujiwara, A González-Martín, P Harter, J W Kim, J Ledermann, E Pujade-Lauraine, M Quinn, K Ochiai, participants of the 5th Ovarian Cancer Consensus Conference; Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference, Annals of Oncology, Volume 28, Issue suppl_8, 1 November 2017, Pages viii30–viii35, https://doi.org/10.1093/annonc/mdx449

Park, S.B., J.B. Kwok, R. Asher, C.K. Lee, P. Beale, F. Selle, and M. Friedlander, Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial. Ann Oncol, November 2017. 28(11): https://www.ncbi.nlm.nih.gov/pubmed/29117336

Lim, K., van Dyk, S., Khaw, P., Veera, J., Mileshkin, L., Ohanessian, L., Harrison, M. and Vinod, S. K. (2017), Patterns of practice survey for brachytherapy for cervix cancer in Australia and New Zealand. J Med Imaging Radiat Oncol.October 2017  https://www.ncbi.nlm.nih.gov/pubmed/28470944

Mercieca-Bebber, R., Friedlander, M., Calvert, M. et al. J A systematic evaluation of compliance and reporting of patient-reported outcome endpoints in ovarian cancer randomised controlled trials: implications for generalisability and clinical practice October (2017) 1: 5. https://doi.org/10.1186/s41687-017-0008-3

Roncolato FT, Berton-Rigaud D, O’Connell R, Lanceley A, Sehouli J, Buizen L, Okamoto A, Aotani E, Lorusso D, Donnellan P, Oza A, Avall-Lundqvist E, Berek J, Hilpert F, Ledermann JA, Kaminsky MC, Stockler MR, King MT, Friedlander M. Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) – Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS). Gynecol Oncol. 2017 Oct 26. pii: S0090-8258(17)31422-1. https://doi.org/10.1016/j.ygyno.2017.10.019

Friedlander, M., R.L. Mercieca-Bebber, and M.T. King, Patient-reported outcomes (PRO) in ovarian cancer clinical trials-lost opportunities and lessons learned. Ann Oncol, October 2017. 27 Suppl 1: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934909/

Clamp, A.R., I. McNeish, A. Dean, D. Gallardo, J. Weon-Kim, D. O’Donnell, J. Hook, C. Coyle, S.P. Blagden, J. Brenton, R. Naik, T. Perren, S. Sundar, A. Cook, E. James, A.M. Swart, S. Stenning, R. Kaplan, and J. Ledermann, 929O_PRICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysis. Annals of Oncology, September 2017. 28(suppl_5): https://oncologypro.esmo.org/Meeting-Resources/ESMO-2017-Congress/BRIM8-a-randomized-double-blind-placebo-controlled-study-of-adjuvant-vemurafenib-in-patients-pts-with-completely-resected-BRAFV600-melanoma-at-high-risk-for-recurrence

Cohen PA, Brand A, Sykes P, et al. Excisional treatment in women with cervical adenocarcinoma in situ (AIS): a prospective randomised controlled non-inferiority trial to compare AIS persistence/recurrence after loop electrosurgical excision procedure with cold knife cone biopsy: protocol for a pilot study. BMJ Open August 2017;7:e017576. https://doi.org/10.1136/bmjopen-2017-017576

Lindemann K, Kok PS, Stockler M, Jaaback K, Brand A. Enhanced recovery after surgery for advanced ovarian cancer: A systematic review of interventions trialed. Int J Gynecol Cancer. 2017 Jul;27(6):1274-1282. https://doi.org/10.1097/IGC.0000000000000981Review. PubMed PMID: 28498237.

Lindemann K, Kok PS, Stockler M, Sykes P, Brand A. Enhanced recovery after surgery for suspected ovarian malignancy: A survey of perioperative practice amongst gynecogical oncologists in Australia and New Zealand to inform a clinical trial. Int J Gynecol Cancer. 2017 Jun;27(5):1046-1050. doi: https://doi.org/10.1097/IGC.0000000000000982

Florence Joly, Felix Hilpert, Aikou Okamoto, Gavin Stuart, Kasunori Ochiai, Michael Friedlander, Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer, European Journal of Cancer, Volume 78, June 2017, Pages 133-138, ISSN 0959-8049, https://doi.org/10.1016/j.ejca.2017.03.019

Bonaventura A1, OʼConnell RL, Mapagu C, Beale PJ, McNally OM, Mileshkin LR, Grant PT, Hadley AM, Goh JCH, Sjoquist KM, Martyn J, DeFazio A, Scurry J, Friedlander ML; Paragon Investigators. Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer. Int J Gynecol Cancer. Jun 2017; 27(5):900–906, https://doi.org/10.1097/IGC.0000000000000978

Roncolato FT, Joly F, O’Connell R, Lanceley A, Hilpert F, Buizen L, Okamoto A, Aotani E, Pignata S, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Heitz F, Feeney A, Berton-Rigaud D, Stockler MR, King M, Friedlander M; GCIG Symptom Benefit group. Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.Oncologist. 2017 Jun 8. pii: theoncologist.2017-0047. https://doi.org/10.1634/theoncologist.2017-0047  [Epub ahead of print] PMID: 28596446

Lindemann K, Kok PS, Stockler M, Jaaback K, Brand A. Enhanced recovery after surgery programs for ovarian cancer – a systematic review to identify candidate interventions. Int J Gynecol Cancer. 2017 May 12. https://doi.org/10.1097/IGC.0000000000000981

Yoland Catherine Antill, Martin R. Stockler, Peey Sei Kok, Kristy Pamela Robledo, Kim Gillies, John Stark, Sonia Yip, Linda R. Mileshkin, and Australia New Zealand Gynaecological Oncology Group (ANZGOG). A phase II trial of durvalumab (Medi 4736) in advanced endometrial cancer: PHAEDRA. Journal of Clinical Oncology May 2017 http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.TPS5614

McGee, M. Bookman, P. Harter, C. Marth, I. McNeish, K. N. Moore, A. Poveda, F. Hilpert, K. Hasegawa, M. Bacon, C. Gatsonis, A. Brand, F. Kridelka, J. Berek, N. Ottevanger, T. Levy, S. Silverberg, B.-G. Kim, H. Hirte, A. Okamoto, G. Stuart, K. Ochiai, and on behalf of the participants of the 5th Ovarian Cancer Consensus Conference; Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors. Ann Oncol January 2017 mdx010. https://doi.org/10.1093/annonc/mdx010

Wilson, E. Pujade-Lauraine, D. Aoki, M. R. Mirza, D. Lorusso, A. M. Oza, A. du Bois, I. Vergote, A. Reuss, M. Bacon, M. Friedlander, D. Gallardo-Rincon, F. Joly, S.-J. Chang, A. M. Ferrero, R. J. Edmondson, P. Wimberger, J. Maenpaa, D. Gaffney, R. Zang, A. Okamoto, G. Stuart, K. Ochiai, and on behalf of the participants of the Fifth Ovarian Cancer Consensus Conference; Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease.Ann Oncol 2016 December mdw663. https://doi.org/10.1093/annonc/mdw663

Rungruang BJ, Miller A, Krivak TC, Horowitz NS, Rodriguez N, Hamilton CA, Backes FJ, Carson LF, Friedlander M, Mutch DG, Goodheart MJ, Tewari KS, Wenham RM, Bookman MA, Maxwell GL, Richard SD. What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study. Cancer. 2017 May 15; 123(6):985-993. https://doi.org/10.1002/cncr.30414 Epub 2016 Nov 16.

Pulford DJ, Harter P, Floquet A, Barrett C, Suh DH, Friedlander M, Arranz JA, Hasegawa K, Tada H, Vuylsteke P, Mirza MR, Donadello N, Scambia G, Johnson T, Cox C, Chan JK, Imhof M, Herzog TJ, Calvert P, Wimberger P, Berton-Rigaud D, Lim MC, Elser G, Xu CF, du Bois A. Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study. BMC Med Ethics. 2016 Oct 21;17(1):63. PubMed PMID: 27769273. https://doi.org/10.1186/s12910-016-0144-y

Jameson MG, McNamara J, Bailey M, Metcalfe PE, Holloway LC, Foo K, Do V, Mileshkin L, Creutzberg CL, Khaw P. Results of the Australasian (Trans-Tasman Oncology Group) radiotherapy benchmarking exercise in preparation for participation in the PORTEC-3 trial. J Med Imaging Radiat Oncol. 2016 Aug; 60(4):554-9. https://doi.org/10.1111/1754-9485.12447 Epub 2016 Apr 5.

de Boer, S.M., M.E. Powell, L. Mileshkin, D. Katsaros, P. Bessette, C. Haie-Meder, P.B. Ottevanger, J.A. Ledermann, P. Khaw, A. Colombo, A. Fyles, M.H. Baron, H.C. Kitchener, H.W. Nijman, R.F. Kruitwagen, R.A. Nout, K.W. Verhoeven-Adema, V.T. Smit, H. Putter, C.L. Creutzberg, and P.s. group, Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol,August  2016. 17(8): https://www.ncbi.nlm.nih.gov/pubmed/27397040

Mercieca-Bebber, R., Friedlander, M., Kok, PS. et al. The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols. (June 2016) 25: 2457. https://doi.org/10.1007/s11136-016-1339-x

Useful Links

HOME

We acknowledge the Traditional Custodians of the lands across Australia on which we live, learn and work and pay respect to Elders past, present and future, acknowledging their continuing connection to land, sea and community.

We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi.

Australia New Zealand Gynaecological Oncology Group www.anzgog.org.au

Level 6, Lifehouse, 119-143 Missenden Road Camperdown NSW 2050 T:+61 2 8071 4880

E: contact@anzgog.org.au © 2025 ANZGOG | Copyright | Disclaimer | ANZGOG Policies | Whistleblower

Go to Top